Clinical Trial Update: A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

View source ↗

Summary

A completed clinical trial comparing resource use, cost, and outcomes in COPD patients taking tiotropium + olodaterol versus fluticasone + umeclidinium + vilant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Tiotropium + Olodaterol (tiotropium/olodaterol)
• fluticasone + umeclidinium + vilanterol

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Status: COMPLETED | Results posted: 2023-11-13